



**MODERN SLAVERY
AND
HUMAN TRAFFICKING
STATEMENT**

CONTENTS

Modern Slavery and Human Trafficking Statement	2
Our Business and Structure	2
The UK, Ireland, and Europe	2
Our Supply Chains	3
Taking action	3

Modern Slavery and Human Trafficking Statement

This statement sets out the actions which Chugai Pharma Europe Limited (CPE) and Chugai Pharma UK Limited (CPU) have taken to understand all potential modern slavery risks related to their businesses and to put in place steps that are aimed at ensuring that there is no slavery or human trafficking in their businesses and supply chains. This statement relates to actions and activities during the financial year 1 January 2016 to 31 December 2016.

Both organisations recognise that they have a responsibility to take a robust approach to slavery and human trafficking and are committed to preventing slavery and human trafficking in their corporate activities, and to ensuring that their supply chains are free from slavery and human trafficking.

Our Business and Structure

Chugai is consistently creating and delivering innovative medicines and is one of Japan's leading pharmaceutical companies.

Founded in 1925, we now employ nearly 7000 people. In addition to our head office in Tokyo our research and development, manufacturing and commercial operations span Germany, France, America, the UK & Ireland, Taiwan, China, Korea, and Singapore.

In 2002, we entered a strategic alliance with F Hoffman-la Roche Limited and we are now focused solely on prescription pharmaceuticals based on our own, as well as Roche's research and development.

The UK, Ireland, and Europe

In 1986, we established our UK representative office to handle the frontline co-ordination for future product clinical development in Europe and marketing anticipation. In 1993, we were formerly established as Chugai Pharma UK Limited (CPU) and were one of the first subsidiaries in Europe to be wholly-owned by a Japanese pharmaceutical company.

In 1994, we expanded our operations and formed Chugai Pharma Europe Limited (CPE) to focus on assessing research drug candidates from Tokyo and provide advice on likely regulatory success in Europe. Initially, CPE was totally focused on development activities and responsible for the European input to Chugai's international product development pipeline as an integral part of the tripartite team structure [based in Japan, North America, and Europe] developing the product candidates from the pre-clinical stage through to Phase III in preparation for launch. However, in June 2015, all subsidiaries in Europe were integrated and reorganised

with CPE serving as an umbrella organisation, in order to oversee all core functions including Research & Development, Commercial (Sales & Marketing), Medical, Safety and Regulatory. In addition, Translational Clinical Research Division (TCRD) was established to rapidly acquire early Proof-of-Concept (PoC) for drugs under development that had been discovered and created in-house.

Our Supply Chains

Our supply chains include drug manufacturers, distributors, and wholesalers.

Taking action

We have contacted representatives in all our supply chain and asked them to provide us with details of any policies / procedures they have in place to prevent modern slavery and human trafficking.

We have also asked our supply chain to furnish us with details of any plans they may have to address these issues.

We will continue to work with our supply chain and other Chugai affiliates to promote good practice and to ensure that our supply chains are free from slavery and human trafficking.